Breast Cancer

View All

Nanoparticles
Now, Nanoparticles for Cancer Treatment

New areas of cancer treatment pop up every now and then without escaping our attention. And this time, it is—getting drugs directly into cancer tumors using Nanoparticles. If the buzz doing the rounds in the industry circles is to be believed, then a new cancer therapy, which will use Nanoparticles to deliver combi...

Find More

Delveinsight
CDK 4/6 Inhibitors- The Changing Paradigm for Breast Cancer Treatment

The discovery of Cyclin Dependent Kinases (CDKs) is a result of increasing number of cancer cases worldwide. The development of CDKs has changed the paradigm for cancer treatment and it has gradually become an interesting area of research in oncology. The research on CDK inhibitors gained momentum because of the fre...

Find More

Dendreon touts; Zytiga slashes risk; Lynparza posts; Dacomitinib wins; Alecensa trounces

Dendreon touts T-cell response data for prostate cancer vaccine Provenge Dendreon has had no shortage of challenges with Provenge since winning FDA approval for the groundbreaking prostate cancer vaccine back in 2010. Years later, the company has unveiled new data showing the med generates a killer T-cell response—a...

Find More

GSK consolidates DT and TT vaccine, AZ gears up for FDA filing, Novartis comes up with flex pricing, Concordia reports loss

GSK consolidates DT and TT vaccine production in Hungary plant, adding 100 jobs With GlaxoSmithKline’s vaccines sales expanding, it figures it needs expanded production as well and some of that will happen at a 10-year-old plant in Hungary as well as Germany. GlaxoSmithKline said on Monday that it would invest £40 m...

Find More

Statistical Insight on Some Common Cancers

Cancer is the leading cause of morbidity and mortality worldwide and one in every seven deaths is due to cancer. It has the worst incidence and mortality statistics. According to the International Agency for Research on Cancer (IARC), an estimated 14.1 million new cases of cancer occur with mortality of 8.2 million ...

Find More

The next generation of ‘weaponized antibody’ therapies

Efforts to develop antibodies that can ferry drugs into cancer cells and minimize damage to healthy tissue are gathering steam. The next generation of these ‘weaponized antibody’ therapies, called antibody–drug conjugates (ADCs), is working its way through clinical trials. The concept that underlies these drugs is s...

Find More

Estrogen Receptor Positive Breast Cancer: Market Outlook

Estrogen Receptor Positive Breast Cancer is the most common type of breast cancer diagnosed in the world. American Cancer Society has found that approximately two out of every three cases of breast cancer are hormone receptor positive. Approximately, 75% of cases of breast cancer are ER- Positive Breast Cancer and t...

Find More

HER2 Expression and its Dynamic Functional States

A research published in Nature recently identified some dynamic functional states in the breast cancer cells of HER2 breast cancer. The research postulates that women who have advanced oestrogen-receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer, are prone to acquire a HER2...

Find More

Delveinsight
Antibody–Drug Conjugates: An Emerging Concept in Cancer Therapy

Antibody–drug conjugates (ADCs), a new weapon of 21st Century for fighting Cancer Traditional cancer chemotherapy was having harsh side effects and also leads to systemic toxicity. The approach was also referred to as the carpet-bombing strategy for fighting cancer. Traditional chemotherapy does not discriminate b...

Find More